Samumed CMO Hopes To Reach Drug Approvals Via The Wnt Pathway
Executive Summary
The clinical-stage biotech has diverse pipeline generated by its Wnt signalling pathway technology platform, and aims to get its first drug to market in 2020.
You may also be interested in...
Top Financings: 2018 Was A Remarkable Year For Biopharma Fundraising
Highlights from the past year's financings include BeiGene's $800m follow-on offering in the US and $903m Hong Kong IPO, Moderna's $560m Series G round and $604m IPO, and Allogene's $300m Series A and $373m IPO.
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.
Reborn Redx Inks Global Licensing Deal With AstraZeneca
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Need a specific report? 1000+ reports available
Buy Reports